KMT2A and leukemia: Given that DOT1L is essential both in development and normal hematopoiesis and given that a significant percent of MLL-rearranged leukemia patients are infants, it is important to develop an alternative, safer therapeutic strategy that does not inhibit key physiological functions of DOT1L.